Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 67-82 , March 2006

Appraisal of the evidence for the clinical use of FFP and plasma fractions

References 

  1. Wallace EL. Monitoring the nation's blood supply. Transfusion. 2003;43:299–301
  2. Wallis JP, Dzik S. Is fresh frozen plasma overtransfused in the United States?. Transfusion. 2004;44(11):1674–1675
  3. Sanguis Study Group . Use of blood products for elective surgery in 43 European hospitals. Transfusion Med. 1994;4:251–268
  4. BCSH guidelines for the use of fresh frozen plasma (updated). Br J Haematol. 2004;126:11–28
  5. BCSH guidelines for the use of fresh frozen plasma. Transfusion Med. 1992;2:57–63
  6. BCSH guidelines: Transfusion guidelines for neonates and older children. Br J Haematol. 2004;124:433–453
  7. College of American Pathologists practice guidelines development taskforce , Lundberg GD. Fresh-frozen plasma, cryoprecipitate and platelets administration. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate and platelets. J Am Med Assoc. 1994;271:777–781
  8. Roseff SD, Luban NLC, Manno CS. Guidelines for assessing appropraiteness of pediatric transfusion. Transfusion. 2002;42:1398–1413
  9. Jones HP, Jones J, Napier JAF, Al-Ismail S. Clinical use of FFP: results of a retrospective process and outcome audit. Transfusion Med. 1998;8:37–41
  10. Eagleton H, Benjamin S, Murphy MF. Audits of the appropriateness of the use of fresh frozen plasma. Transfusion Med. 2000;10(supplment 1):6
  11. American Association of Blood Banks. Blood Transfusion Therapy: a Physician's Handbook. 7th edn, Triulzi DJ, editors.
  12. McClelland DBL. Fresh frozen plasma—opinion and evidence. Transfusion Med. 1992;2:97–98
  13. Cohen H. Avoiding the misuse of fresh frozen plasma. Br Med J. 1987;307:395–396
  14. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. Br Med J. 1996;312:71–72
  15. Todd AAM. Evidence-based use of blood products. Curr Paediatr. 2002;12:304–309
  16. Straus S, Jones G. What has evidence based medicine done for us?. BMJ. 2004;329:987
  17. Schnatter A. Research evidence and the individual patient. Quart J Med. 2003;96:1–5
  18. Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care. Meta-Analysis in Context. 2nd edn. London: BMJ Publishing Group; 2001;
  19. Sackett DL, Strauss SE, Richardson WS, et al. Evidence Based Medicine: how to Practice and Teach EBM. 2nd edn. Churchill Livingstone; 2000;
  20. Guyatt GH, Rennie D. Users’ Guide to the Medical Literature: Essentials of Evidence-Based Clinical Practice. American Medical Association; 2002;
  21. Guidelines: BCSH. The diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556–573
  22. Shehata N, Kouroukis C, Kelton JG. A review of randomized controlled trials using therapeutic apheresis. Transfusion Med Rev. 2002;16:200–229
  23. Stanworth SJ, Brunskill S, Hyde C, et al. Br J Haematol. 2004;126:139–152
  24. De Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med. 2001;29:1261–1267
  25. Pamphilon DH. Viral Inactivation of FFP. Br J Haematol. 2000;109:680–693
  26. Alderson P, Groves T. What doesn't work and how to show it. BMJ. 2004;328:473
  27. Chalmers I. Well informed uncertainties about the effects of treatments. BMJ. 2004;328:475–476
  28. Doust J, Del Mar C. Why do doctors use treatments that do not work?. BMJ. 2004;328:474–475
  29. SHOT: Serious hazards of Transfusion report 2001–2002. SHOT Steering Committee July 2003. ISBN No. 0 9532 789 5 6.
  30. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfusion Med Rev. 2003;17:120–162
  31. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep. 2004;3:324–330
  32. McVay PA, Toy PTCY. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747–753
  33. Peterson GA. Does systematic anticoagulation increase the risk of internal jugular vein cannulation? (letter). Anesthesiology. 1991;75:1124
  34. Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol. 2004;125:69–73
  35. Hirshberg A, Dugas M, Banez EI, et al. Minimising dilutional coagulopathy in exsanuinating haemorrhage: a computer simulation. J Trauma. 2003;54:454–463
  36. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared to fresh frozen plasma. Blood Coagul Fibrinolysis. 2003;14:283–287
  37. Leebeek FWG, Schipperus MR, van Vliet HH. Coagulation factor levels in solvent/detergent-treated plasma. Transfusion. 1999;39:1150–1151
  38. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121:778–785
  39. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548–1552
  40. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion. 2003;43:1322–1329
  41. Northern Neonatal Nursing Initiative (NNNI) Trial Group , McCoy , et al. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. Eur J Pediat. 1996;155:580–588
  42. Leese T, Holliday M, Heath D, et al. Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg. 1987;74:907–911
  43. Northern Neonatal Nursing Initiative (NNNI) Trial Group , Tin , et al. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose in preterm babies: outcome at 2 years. Lancet. 1996;348:229–232
  44. Dzik S. The use of blood components prior to invasive bedside procedures: a critical appraisal. Transfusion Therapy: Clinical Principles and Practice. American Association Blood Banks; 1999;
  45. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc. 1995;273:408–412
  46. Heddle NM, Cook RJ, Webert KE, et al. Biomedical Excellence for Safer Transfusion Working Party of the International Society for Blood Transfusion. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion. 2003;43:742–752
  47. Begg CB, Cho MK, Eastwood S, et al. Improving the quality of reporting of randomised controlled trials: the CONSORT statement. J Am Med Assoc. 1996;276:637–639
  48. Casbard AC, Williamson LM, Murphy MF, et al. The role of prophylactic fresh frozen plasma in reducing blood loss and correcting coagulopathy in cardiac surgery: a systematic review. Anaesthesia. 2004;59:550–558
  49. Wu YY, Snyder El. Safety of the blood supply: role of pathogen reduction. Blood Rev. 2003;17:111–122
  50. Srivastava A. Dose and response in haemophilia—optimization of factor replacement therapy. Br J Haematol. 2004;137:12–25
  51. Roberts I, Alderson P, Bunn F, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. The Cochrane Database of Systematic Reviews 2004; Issue 4. Art. No.: CD000567.pub2. DOI: 10.1002/14651858.CD000567.pub2.
  52. Bunn F, Alderson P & Hawkins V. Colloid solutions for fluid resuscitation. The Cochrane Database of Systematic Reviews 2003; Issue 1. Art. No.: CD001319. DOI: 10.1002/14651858.CD001319.
  53. SAFE study investigators . A comparison of albumin and saline for fluid resuscitation in the intensive care unit. NEJM. 2004;350:2247–2256
  54. Jardine LA, Jenkins-Manning S & Davies MW. Albumin infusion for low serum albumin in preterm newborn infants. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD004208.pub2. DOI: 10.1002/14651858.CD004208.pub2.
  55. Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10(3):165–169
  56. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43(10):1460–1480
  57. Bierling P, Godeau B. Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang. 2004;86:8–14
  58. Hughes RAC, Raphaël JC, Swan AV & van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. The Cochrane Database of Systematic Reviews 2004; Issue 1. Art. No.: CD002063.pub2. DOI: 10.1002/14651858.CD002063.pub2.
  59. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004000. DOI: 10.1002/14651858.CD004000.
  60. Gray OM, McDonnell GV & Forbes RB. Intravenous immunoglobulins for multiple sclerosis. The Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD002936. DOI: 10.1002/14651858.CD002936.
  61. Alcock GS & Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. The Cochrane Database of Systematic Reviews 2002; Issue 3. Art. No.: CD003313. DOI: 10.1002/14651858.CD003313.
  62. Ohlsson A & Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. The Cochrane Database of Systematic Reviews 2004; Issue 1. Art. No.: CD000361.pub2. DOI: 10.1002/14651858.CD000361.pub2.
  63. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39(1):38–46
  64. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241–251
  65. Jones ML, Wray J, Wight J, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG. 2004;111(9):892–902
  66. Crowther C & Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. The Cochrane Database of Systematic Reviews 1997; Issue 2. Art. No.: CD000021. DOI: 10.1002/14651858.CD000021.
  67. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci. 2003;28(3):249–255
  68. United Kingdom haemophilia centre doctors'organidation (UKHCDO) . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2003;9:1–23
  69. Wiel E, Vallet B, Girbes ARJ, Polderman KH. A definite role for treatment with activated protein C in sepsis? Yes/standard use is premature. J Thromb Haemostasis. 2003;1:2469–2471
  70. Pocock SJ, Elbourne DR. Randomised trials or observational tribulations. N Engl J Med. 2000;342:1907–1909

PII: S1521-6926(05)00050-2

doi: 10.1016/j.beha.2005.01.036

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 67-82 , March 2006

Article Tools

* Image Usage & Resolution